Harte-Hanks Overview
Get informed when a big investor buys or sells
+ Follow-34.96%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HHS is -34.96%. That is below the Consumer Discretionary sector average of 24.0%. Investors often review this figure alongside Harte-Hanks's historical trend and sector peers before judging valuation or financial health.
Against Consumer Discretionary companies, HHS currently prints -34.96% for ROE, while the sector average sits near 24.0%. That is roughly 245.7% below the sector mean. Large gaps often invite a closer look at Harte-Hanks's growth, margins, and balance sheet.
Return on Equity shows how effectively Harte-Hanks converts resources into returns. At -34.96%, HHS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HHS's ROE (-34.96%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Harte-Hanks's ROE against similar Consumer Discretionary names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Discretionary companies and their key multiples and fundamentals.
